{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.0","upperLimit":"20.9","value":"16.7"},{"groupId":"OG001","lowerLimit":"17.5","upperLimit":"26.2","value":"21.6"},{"groupId":"OG002","lowerLimit":"24.6","upperLimit":"34.2","value":"29.2"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.8","upperLimit":"17.0","value":"13.1"},{"groupId":"OG001","lowerLimit":"15.5","upperLimit":"23.8","value":"19.4"},{"groupId":"OG002","lowerLimit":"25.9","upperLimit":"35.6","value":"30.6"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"17.6","value":"13.7"},{"groupId":"OG001","lowerLimit":"18.2","upperLimit":"27.0","value":"22.4"},{"groupId":"OG002","lowerLimit":"21.3","upperLimit":"30.5","value":"25.7"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"366"},{"groupId":"OG002","value":"366"}],"units":"Participants"}],"description":"Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The analysis was performed for each region and for each of the blinded independent readers","dispersionType":"95% Confidence Interval","groups":[{"description":"Prostate or prostate bed","id":"OG000","title":"Prostate/ Prostate Bed"},{"description":"Pelvic Lymph Nodes","id":"OG001","title":"Pelvic Lymph Nodes"},{"description":"Other (extra-pelvic) sites","id":"OG002","title":"Other (Extra-pelvic) Sites"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Population (EAP): all patients who received rhPSMA-7.3 (18F) injection followed by a PET/CT scan and for whom sufficient data are available to permit a clear classification following the SoT algorithm.","reportingStatus":"POSTED","timeFrame":"Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan","title":"CDR of rhPSMA-7.3 (18F) PET in the Following Regions: Prostate/Prostate Bed, Pelvic Lymph Nodes, Other","type":"SECONDARY","unitOfMeasure":"percentage"}